Wed, Jun 07, 2017 - Page 10 News List

US FDA mulling generic drug initiative

LOWERING COSTS:The agency is also looking into publishing a list of brand-name drugs whose patent protection has lapsed and do not face any generic competition

Bloomberg

The head of the US Food and Drug Administration (FDA) is considering using the agency’s powers to bring more price competition to the market for generic drugs, targeting high-priced products by prioritizing the approval of additional competing treatments.

FDA Commissioner Scott Gottlieb said in an interview on Monday that the agency is looking at how to push applications to the front of the line in cases where there are fewer than three competing generic manufacturers.

The policy would target cases where there are few or no competing versions of drugs, which has led to high prices in some situations.

In one now-infamous case, Turing Pharmaceuticals AG, then led by Martin Shkreli, bought the rights to sell a decades-old anti-infective drug called Daraprim and raised the price from US$13.50 to US$750 per pill.

Valeant Pharmaceuticals International Inc has likewise benefited from older drugs with limited competition, such as two treatments for the rare condition Wilson’s Disease. Valeant bought the treatments and raised their prices by about 30-fold.

Adding generic competitors would mean lower prices, Gottlieb said, adding that the goal is to have three manufacturers of every generic version of a drug.

That is the point at which prices start to fall significantly, he said.

“We know the most significant savings to consumers comes when there are three generics on the market,” Gottlieb said in a telephone interview.

US President Donald Trump has said he wants to address the issue of high US pharmaceutical prices, and drug executives last week said they expected the administration to act soon.

The first generic drug that hits the market will “only slightly lower” the price compared to the brand version, an FDA analysis said.

A second generic competitor approved would slash the price to almost half that of the brand version, while subsequent approvals would drop the cost to 20 percent of the brand version, it added.

The action on generic drugs would be a shift from the agency’s current stance; the FDA prioritizes applications for the first company to apply for a generic version of a brand-name product.

The agency has not typically considered drug costs as a major policy and is barred from taking them into account when deciding whether to approve a new drug.

The move is one of several actions Gottlieb said he plans to take to address drug costs.

The agency is also looking at a plan to eliminate within a year the backlog of 2,640 generic drug applications, Gottlieb said.

Other ideas Gottlieb has referenced include looking into ways to thwart brand-name drugmakers from using programs to restrict distribution of their products to keep generic drug manufacturers from accessing enough product for testing, which he said can require as many as 3,000 pills.

“Getting access to 3,000 tablets can be hard unless the branded companies are going to facilitate the ability of the generic companies to get the drug,” Gottlieb said. “They can’t just go into the market and buy it readily.”

The FDA is also looking into whether it can publish a list of the 180 brand-name drugs that no longer have patent protection and still do not face any generic competition, 150 of which the agency has never received an application from a generic drugmaker to review.

Publishing the list “might create a more compelling business opportunity,” Gottlieb said.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top